Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for metabolic conditions marked by persistent glucose imbalances, primarily serving the United States market. Its flagship product candidate, RZ358, a human monoclonal antibody, is currently progressing through Phase 2b clinical trials as a potential treatment for congenital hyperinsulinism, an exceptionally rare genetic disorder impacting pediatric patients. The company is also developing RZ402, a powerful and selective plasma kallikrein inhibitor, which is in Phase 1 clinical evaluation for the ongoing management of diabetic macular edema.